Reva Medical

REVA Medical, LLC is a medical device company focused on the development of bioresorbable polymers for vascular applications, with a mission to restore patient health for life through the application of biomaterials in the development and sale of implantable medical devices. The company is a pioneer of novel bioresorbable polycarbonate polymers derived from the naturally occurring tyrosine amino acid, and in its 20-year history has developed 19 polymer families. Its first commercial polymer is Tyrocore, invented for bioresorbable vascular scaffolds and used to make Fantom Encore, a drug-eluting bioresorbable scaffold for the treatment of coronary artery disease that is currently available for sale in select European countries. REVA also offers the MOTIV Bioresorbable Scaffold, designed for treating below-the-knee peripheral artery disease, and TyroSphere bioresorbable embolic microspheres designed to treat hypervascular tumors.

REVA Medical, LLC is a medical device company focused on the development of bioresorbable polymers for vascular applications. REVA is a pioneer of novel bioresorbable polycarbonate polymers derived from the naturally occurring tyrosine amino acid, and in its 20-year history the company has developed 19 polymer families. The company's first commercial polymer is Tyrocore, which was invented for bioresorbable vascular scaffolds. Tyrocore is used to make Fantom Encore, a drug-eluting bioresorbable scaffold for the treatment of coronary artery disease; Fantom Encore is currently available for sale in select European countries. Fantom Encore was developed as an alternative to metallic stents to restore blood flow to blocked coronary arteries, and unlike permanent metallic stents, bioresorbable scaffolds are designed to resorb from the body over time, which is intended to improve long-term outcomes and further treatment options for patients. REVA also offers the MOTIV Bioresorbable Scaffold, designed specifically for treating below-the-knee peripheral artery disease and made with Tyrocore; MOTIV is described as the first bioresorbable scaffold to obtain CE Mark approval for the treatment of BTK disease and has also received FDA Breakthrough Technology Status in the US. TyroSphere beads are bioresorbable embolic microspheres designed to treat hypervascular tumors, offering both safe degradation/resorption and radiopacity so they are visible under standard x-ray to aid precise delivery to the targeted tumor.

A leader in bioresorbable polymer technologies for vascular applications.

• Tyrocore

  REVA's proprietary polymer invented specifically for implantable bioresorbable medical devices; the company's first commercial polymer, used to make Fantom Encore.

• Fantom Encore

  A third-generation drug-eluting bioresorbable scaffold (BRS) made with Tyrocore for the treatment of coronary artery disease, offering radiopacity, ease-of-use, and the thinnest struts of any commercially available CE Mark BRS; currently available for sale in select European countries.

• MOTIV Bioresorbable Scaffold

  A bioresorbable scaffold designed specifically for treating below-the-knee (BTK) peripheral artery disease, made with Tyrocore; described as the first bioresorbable scaffold to obtain CE Mark approval for BTK treatment and to receive FDA Breakthrough Technology Status in the US.

• TyroSphere

  Bioresorbable embolic microspheres designed to treat hypervascular tumors, offering safe degradation/resorption and radiopacity for visibility under standard x-ray.

• 2020-01-15

  Reva Medical files for Chapter 11 bankruptcy[4]Reva Medical 申请第 11 章破产保护sandiegouniontribune.com

  Reported: 2020-01-16

  Reva Medical filed a Chapter 11 bankruptcy petition in Delaware as part of a pre-packaged effort to restructure its debt.

1. 1Bioresorbable Polymers for Vascular Scaffolds | REVArevamedical.com
2. 2Our Company | REVArevamedical.com
3. 3Reva Medical (United States)wikidata.org
4. 4Reva Medical 申请第 11 章破产保护sandiegouniontribune.com